Articles published by Moderna, Inc.
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
January 10, 2022
From Moderna, Inc.
Via AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
January 05, 2022
From Moderna, Inc.
Via AccessWire
Tickers
MRNA
Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
January 04, 2022
From Moderna, Inc.
Via AccessWire
Tickers
MRNA
Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference
January 03, 2022
From Moderna, Inc.
Via AccessWire
Tickers
MRNA
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
December 27, 2021
From Moderna, Inc.
Via AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
December 27, 2021
From Moderna, Inc.
Via AccessWire
Exposures
COVID-19
Tickers
MRNA
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
December 20, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
December 13, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
December 10, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
December 09, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna to Present at Upcoming Investor Conferences in December 2021
November 22, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
November 19, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
November 19, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine
November 18, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
November 17, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years
November 17, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older
November 15, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting
November 12, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
November 04, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
November 02, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents
October 31, 2021
From Moderna, Inc.
Via Business Wire
Tickers
MRNA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free